RIGEL PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M | $108.6M | $59.3M | $44.5M |
| Cost of Revenue | $19.6M | $18.6M | $7.1M | $1.7M | $1.1M | $895.0K | $906.0K | $287.0K |
| Gross Profit | $274.7M | $160.6M | $109.8M | $118.5M | $148.2M | $107.7M | $58.4M | $44.2M |
| Gross Margin | 93.3% | 89.6% | 93.9% | 98.5% | 99.3% | 99.2% | 98.5% | 99.4% |
| Operating Expenses | ||||||||
| Research & Development | $33.3M | $23.4M | $24.5M | — | — | — | — | — |
| SG&A Expense | $115.9M | $113.1M | $105.7M | $112.5M | $91.9M | $76.6M | $74.6M | $70.0M |
| Operating Income | $125.5M | $24.2M | $-20.5M | $-55.6M | $-12.5M | $-29.0M | $-69.1M | $-72.7M |
| Operating Margin | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% | -26.7% | -116.5% | -163.3% |
| Interest Expense | — | $7.9M | $6.9M | $3.7M | $4.9M | $1.4M | $335.0K | — |
| Pretax Income | $121.8M | $18.4M | $-25.1M | $-58.6M | $-17.3M | $-29.7M | $-66.9M | — |
| Income Tax Expense | $-245.2M | $881.0K | $0 | — | $605.0K | — | — | $0 |
| Net Income | $367.0M | $17.5M | $-25.1M | $-58.6M | $-17.9M | $-29.7M | $-66.9M | $-70.5M |
| Net Margin | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% | -112.8% | -158.3% |
| EPS (Basic) | $20.40 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 | $-0.40 | $-0.44 |
| EPS (Diluted) | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 | $-0.40 | $-0.44 |
| Shares Outstanding (Basic) | 18.0M | 17.6M | 17.4M | 17.0M | 170.5M | 168.8M | 167.4M | 167.2M |
| Shares Outstanding (Diluted) | 18.8M | 17.7M | 17.4M | 17.0M | 170.5M | 168.8M | 167.4M | 167.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |